Expertise in
23
conditions

Dr. Michael O. Ojelabi

Oncology
Gundersen Pharmacy
1836 South Ave, 
La Crosse, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
23
conditions
Gundersen Pharmacy
1836 South Ave, 
La Crosse, WI 

Overview

Michael Ojelabi is an Oncologist practicing medicine in La Crosse, Wisconsin.

Dr. Ojelabi is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Gallbladder Adenocarcinoma, and Gallbladder Cancer.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 25 clinical trials. Dr. Ojelabi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IL

Hospital Affiliations

Gundersen Boscobel Area Hospital And Clinics
Gundersen St Josephs Hospital And Clinics
Gundersen Lutheran Medical Center
Crossing Rivers Health Medical Center
Tomah Memorial Hospital

Languages Spoken

English
Yoruba

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 14 Less Insurance Carriers -

Locations

Gundersen Pharmacy
1836 South Ave, La Crosse, WI 54601

Additional Areas of Focus

Dr. Ojelabi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Lenalidomide, Methotrexate, Nivolumab, Rituximab
Study Phase: Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Other, Procedure, Biological, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

4 Total Publications

Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901).
Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901).
Journal: Journal of the National Cancer Institute
Published: January 27, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Gundersen Pharmacy

1836 South Ave, 
La Crosse, WI 
 (0.1 miles away)
608-782-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kurt Oettel is an Oncologist practicing medicine in La Crosse, Wisconsin. Dr. Oettel is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Oettel is currently accepting new patients.

Expertise in
51
conditions
Dr. Paula Gill
Hematology | Oncology
Expertise in
51
conditions
Dr. Paula Gill
Hematology | Oncology
Referral may be required

Mayo Clinic Health System In Lacrosse

700 West Ave S, 
La Crosse, WI 
 (0.7 miles away)
608-782-9760
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paula Gill is a Hematologist and an Oncologist practicing medicine in La Crosse, Wisconsin. Dr. Gill is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Gill is currently accepting new patients.

Expertise in
12
conditions
Dr. Hamid Emamekhoo
Oncology | Hematology Oncology | Hematology
Expertise in
12
conditions
Dr. Hamid Emamekhoo
Oncology | Hematology Oncology | Hematology
Referral may be required

University Of Wisconsin Medical Foundation Inc

1040 Division St, 
Mauston, WI 
 (58.4 miles away)
608-847-7355
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamid Emamekhoo is an Oncologist and a Hematologist Oncology provider practicing medicine in Mauston, Wisconsin. Dr. Emamekhoo is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy. Dr. Emamekhoo is currently accepting new patients.

Frequently Asked Questions about Dr. Michael O. Ojelabi

How do I make an appointment with Dr. Michael O. Ojelabi?

You can book an appointment with Dr. Michael O. Ojelabi by calling their office at 608-782-7300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael O. Ojelabi a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael O. Ojelabi is classified as an Distinguished expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael O. Ojelabi specialize in?

While Dr. Michael O. Ojelabi is a Oncology, they have specific expertise in Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Gallbladder Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Michael O. Ojelabi participate in research or clinical trials?

Yes. Dr. Michael O. Ojelabi has published 4 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Dr. Michael O. Ojelabi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael O. Ojelabi accept my insurance?

Dr. Michael O. Ojelabi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 608-782-7300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ojelabi's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 62 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile